CRIS Current Research Information System

MOLLICA, VERONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.603
NA - Nord America 3.088
EU - Europa 2.256
SA - Sud America 349
AF - Africa 294
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.595
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.021
SG - Singapore 2.041
CN - Cina 1.746
IT - Italia 661
VN - Vietnam 547
HK - Hong Kong 476
KR - Corea 379
BR - Brasile 264
SE - Svezia 262
DE - Germania 246
NL - Olanda 205
IN - India 201
GB - Regno Unito 173
FI - Finlandia 134
CH - Svizzera 114
CI - Costa d'Avorio 113
SC - Seychelles 108
RU - Federazione Russa 103
IE - Irlanda 92
FR - Francia 80
JP - Giappone 59
CA - Canada 43
BG - Bulgaria 42
ID - Indonesia 41
AR - Argentina 38
PL - Polonia 37
JO - Giordania 32
AT - Austria 30
TG - Togo 29
ES - Italia 18
MX - Messico 18
ZA - Sudafrica 17
TR - Turchia 16
BD - Bangladesh 14
CL - Cile 11
UA - Ucraina 10
CO - Colombia 9
NG - Nigeria 9
LT - Lituania 8
PK - Pakistan 8
PT - Portogallo 8
VE - Venezuela 8
EC - Ecuador 7
BE - Belgio 5
PE - Perù 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
GR - Grecia 4
HU - Ungheria 4
KE - Kenya 4
KZ - Kazakistan 4
MY - Malesia 4
TH - Thailandia 4
TW - Taiwan 4
DO - Repubblica Dominicana 3
EE - Estonia 3
GH - Ghana 3
HR - Croazia 3
IQ - Iraq 3
IR - Iran 3
PS - Palestinian Territory 3
RO - Romania 3
RS - Serbia 3
UZ - Uzbekistan 3
AL - Albania 2
AU - Australia 2
AZ - Azerbaigian 2
CY - Cipro 2
EG - Egitto 2
IL - Israele 2
PH - Filippine 2
TN - Tunisia 2
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CD - Congo 1
DZ - Algeria 1
EU - Europa 1
GN - Guinea 1
GT - Guatemala 1
HN - Honduras 1
IS - Islanda 1
KI - Kiribati 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MD - Moldavia 1
MK - Macedonia 1
ML - Mali 1
MZ - Mozambico 1
PA - Panama 1
SA - Arabia Saudita 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 11.595
Salva come PNG Salva come JPEG
Città #
Singapore 1.391
Hefei 794
Hong Kong 470
Ashburn 446
Seoul 375
Santa Clara 230
Beijing 200
Boardman 191
Chandler 168
Bologna 161
Ho Chi Minh City 160
Los Angeles 128
Hanoi 118
Abidjan 113
Bern 111
Fairfield 109
Helsinki 107
Southend 107
Dublin 91
San Jose 88
Dallas 81
Milan 76
Bengaluru 73
Princeton 61
Redondo Beach 55
Seattle 55
Buffalo 54
New York 53
Tokyo 50
Houston 46
Turin 46
Sofia 42
Woodbridge 40
Cambridge 38
Wilmington 38
Guangzhou 35
Boydton 33
Amman 32
Nuremberg 32
Frankfurt am Main 29
Lomé 29
Munich 29
Dong Ket 28
Rome 28
Tongling 28
São Paulo 27
Jakarta 26
Ann Arbor 24
Chicago 24
Shanghai 23
Warsaw 23
Florence 21
Lappeenranta 20
Paris 20
Redmond 20
Berlin 19
Falkenstein 19
Vienna 19
Denver 17
Hyderabad 15
Phoenix 15
London 14
Montreal 14
Amsterdam 13
Des Moines 13
Haiphong 13
Moscow 13
Biên Hòa 12
Boston 12
Da Nang 12
Redwood City 12
Toronto 12
Bühl 11
Orem 11
Stockholm 11
Zhengzhou 11
Brooklyn 10
Castel Maggiore 10
Jinan 10
Nanjing 10
Verona 10
Abeokuta 9
Changsha 9
San Diego 9
Westminster 9
Xi'an 9
Atlanta 8
Harbin 8
Salt Lake City 8
San Francisco 8
Shenzhen 8
Thái Nguyên 8
Tianjin 8
Yubileyny 8
Arezzo 7
Bari 7
Bexley 7
Buenos Aires 7
Chongqing 7
Hải Dương 7
Totale 7.386
Salva come PNG Salva come JPEG
Nome #
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 277
Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer 238
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 209
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 187
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data 184
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 184
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 183
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 176
H&E and OCT4/CD34 for the assessment of lympho-vascular invasion in seminoma and embryonal carcinoma 175
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 169
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study 142
Bone targeting agents in patients with metastatic prostate cancer: State of the art 140
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 139
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 136
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 133
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 133
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 133
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations 132
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 132
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 131
TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis 128
Mutations of NOTCH Genes as an Alternative Mechanism to Activate mTOR pathway in Low-grade Oncocytic Tumor (LOT) of the Kidney 126
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 125
FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type 124
The human microbiota and prostate cancer: Friend or foe? 124
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 123
Belzutifan: enhancing the blockade of angiogenesis in renal cell carcinoma 119
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study 118
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 117
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. 114
Is There a Role for Immunotherapy in Prostate Cancer? 114
Genomics and Immunomics in the Treatment of Urothelial Carcinoma 113
Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT 113
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 112
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics 112
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes 111
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 109
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 109
Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough 105
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 101
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System 100
The functioning side of the pancreas: a review on insulinomas 98
Third-and later-line treatment in advanced or metastatic gastric cancer: A systematic review and meta-analysis 96
Metabolomic profiling in renal cell carcinoma patients: News and views 95
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors 95
Characterization of testicular embryonic-type neuroectodermal tumor and embryonic-type neuroectodermal tissue admixed with mature neuro-glial tissue using a broad immunohistochemical panel 94
Renal Tumors with Oncocytic and Papillary Features: A Phenotypic and Genotypic Study 94
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 93
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 93
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma 93
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives 92
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 92
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 91
Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma 90
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 90
Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report 86
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 83
SOX2 and PRAME in the "reprogramming" of seminoma cells 83
Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer 82
Effect on outcomes of toxicity-related dose reduction in TKI monotherapy or TKI-IO combination therapy for advanced renal cell carcinoma 81
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences 81
A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34 81
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients 80
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 80
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis 78
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 78
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 76
Oncology clinical trials in the time of COVID-19: How a pandemic can revolutionize patients' care 76
Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data 76
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 73
Cancer immunotherapy: Current and future perspectives on a therapeutic revolution 72
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma 72
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 70
Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis 69
Treating prostate cancer by antibody-drug conjugates 68
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 67
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials 66
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 64
Molecular mechanisms related to hormone inhibition resistance in prostate cancer 64
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents 64
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 62
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 59
Microbiota and prostate cancer 59
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 58
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 58
Cabazitaxel in metastatic prostate cancer 57
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 57
Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis 57
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 57
Immunophenotypical assessment supports that post-chemotherapy glandular tumours of germ cell origin straddle between glandular yolk sac tumour and ‘somatic-type’ adenocarcinoma 57
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 56
Pembrolizumab plus enfortumab vedotin in urothelial cancer 55
Yolk sac tumor of postpubertal-type does not exhibit immunohistochemical loss of SMARCB1/INI1 and SMARCA4/BRG1…but choriocarcinoma? 55
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer 55
Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia in Situ, and Germ Cell Tumors of the Testis 55
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 53
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis 51
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 51
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 51
Towards a new WHO classification of renal cell tumor: What the clinician needs to know-a narrative review 51
Totale 10.040
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.451
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.451
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021226 0 0 0 0 0 0 1 20 37 25 11 132
2021/2022533 8 15 16 36 38 22 33 62 65 25 144 69
2022/20231.438 58 99 44 82 132 179 93 94 239 55 158 205
2023/2024753 87 96 64 65 51 100 22 78 40 57 46 47
2024/20253.521 149 429 312 222 417 145 236 159 64 254 406 728
2025/20265.084 909 1.182 904 744 819 305 221 0 0 0 0 0
Totale 11.938